Xanomeline-Trospium Improves Schizophrenia Symptoms in Phase 3 Trial
The phase 3 EMERGENT-2 trial included 252 patients with schizophrenia who were experiencing symptoms of psychosis.
General Psychiatry
FDA Rejects Pimavanserin sNDA for Alzheimer Disease Psychosis
The sNDA for Alzheimer disease psychosis included data from the phase 3 HARMONY and phase 2 Study-019 trials.
Intranasal Therapy Misses Endpoint in Social Anxiety Disorder Trial
Patients received PH94B or placebo intranasally 20 minutes before an induced public speaking challenge to relieve symptoms of anxiety.
TMS Device NeuroStar Cleared for Anxious Depression
NeuroStar Advanced Therapy for Mental Health is a transcranial magnetic stimulation system that uses magnetic fields to reignite dormant synapses in the brain.
Electroacupuncture May Aid Depression-Related Insomnia
Quality of sleep significantly improved compared with standard care alone or sham acupuncture
Court Looks at When Medication May Be Administered Without Patient Consent
The patient had been diagnosed with schizophrenia, and suffered from auditory and visual hallucinations, delusions, and extreme paranoia.
Zulresso Indication Expanded to Include Younger Patients With Postpartum Depression
The expanded approval was based on safety data from an open-label study in 20 patients aged 15 to 17 years with postpartum depression.
FDA Panel Votes on Pimavanserin for Alzheimer Disease Psychosis
Although not bound by the committee’s recommendations, the Agency does take them into consideration when making decisions on approval.
Actions Against Physician Licenses Due to Substance Use Down
However, despite declines from 2004 to 2020, substance use-related actions remain much higher than actions for physical, psychological impairment
Pediatric Suspected Suicides by Poisoning Up, Including Among Younger Ages
Easy access to over-the-counter medications may play a role in their use for suspected suicides
